Sequencing T Cell Redirection Therapies Leads to Deep and Durable Responses in Relapsed/Refractory Myeloma Patients

Investigators showed that the sequential use of different T cell redirection therapies was possible and could lead to deep and durable responses following relapse after bispecific antibody therapy in relapsed/refractory multiple myeloma.